Media coverage about pSivida Corp. (NASDAQ:PSDV) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. pSivida Corp. earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.1818067400783 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several research analysts have commented on the company. HC Wainwright set a $5.00 target price on pSivida Corp. and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Laidlaw began coverage on pSivida Corp. in a research note on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $8.00.
pSivida Corp. (PSDV) traded down $0.10 during trading on Tuesday, hitting $1.28. The company’s stock had a trading volume of 1,082,000 shares, compared to its average volume of 506,644. pSivida Corp. has a 52-week low of $1.03 and a 52-week high of $2.45.
pSivida Corp. (NASDAQ:PSDV) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). pSivida Corp. had a negative return on equity of 139.56% and a negative net margin of 226.31%. The firm had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.74 million. sell-side analysts anticipate that pSivida Corp. will post -0.59 earnings per share for the current fiscal year.
About pSivida Corp.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.